Dolby Laboratories, Inc.
For the period ended Jun 27, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 27, 2025 · Filed Jul 31, 2025
DLB$64.67-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim Condensed Consolidated Statements of Cash Flows
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Fiscal Year-To-Date Ended | ||
|---|---|---|
| June 27,2025 | June 28,2024 | |
| Operating activities: | ||
| Net income including noncontrolling interest | $206,838 | $205,450 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 65,829 | 54,199 |
| Stock-based compensation | 97,462 | 90,146 |
| Amortization of operating lease right-of-use assets | 8,193 | 8,745 |
| Amortization of premium on investments | — | (2,586) |
| Provision for/(benefit from) credit losses | 2,582 | (2,382) |
| Deferred income taxes | (9,146) | (18,009) |
| Other non-cash items affecting net income | (17,553) | (6,181) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 15,234 | (21,319) |
| Contract assets, net | (6,902) | (8,642) |
| Inventories | 4,020 | (4,615) |
| Operating lease right-of-use assets | (1,717) | (7,681) |
| Prepaid expenses and other assets | 46,972 | 7,527 |
| Accounts payable and accrued liabilities | (48,979) | (80,837) |
| Income taxes, net | 1,895 | 15,265 |
| Contract liabilities | (1,061) | (3,189) |
| Operating lease liabilities | (8,237) | (2,577) |
| Other non-current liabilities | (6,063) | (12,232) |
| Net cash provided by operating activities | 349,367 | 211,082 |
| Investing activities: | ||
| Purchases of marketable securities | — | (147,646) |
| Proceeds from sales of marketable securities | 15,911 | 4,451 |
| Proceeds from maturities of marketable securities | — | 140,839 |
| Proceeds from sale of assets held for sale | 16,881 | — |
| Purchases of property, plant, and equipment | (20,104) | (22,628) |
| Business combinations, net of cash and restricted cash acquired, and other related payments | (1,362) | — |
| Net cash provided by/(used in) investing activities | 11,326 | (24,984) |
| Financing activities: | ||
| Proceeds from issuance of common stock | 38,681 | 39,487 |
| Repurchase of common stock | (89,990) | (139,999) |
| Payment of excise tax on repurchase of common stock | (261) | — |
| Payment of cash dividend | (95,010) | (85,971) |
| Distributions to noncontrolling interest | (1,449) | (4,507) |
| Shares repurchased for tax withholdings on vesting of restricted stock | (35,154) | (37,428) |
| Equity issued in connection with business combination | — | 722 |
| Net cash used in financing activities | (183,183) | (227,696) |
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash | 1,302 | 2,256 |
| Net increase/(decrease) in cash, cash equivalents, and restricted cash | 178,812 | (39,342) |
| Cash, cash equivalents, and restricted cash at beginning of period | 577,752 | 817,966 |
| Cash, cash equivalents, and restricted cash at end of period | $756,564 | $778,624 |
| Supplemental disclosure: | ||
| Cash paid for income taxes, net of refunds received | $58,520 | $50,763 |
| Non-cash investing activities and financing activities: | ||
| Change in property, plant, and equipment purchased, unpaid at period-end | $10,738 | $6,146 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.